Edgewise Therapeutics (EWTX) Operating Leases (2022 - 2026)

Edgewise Therapeutics has reported Operating Leases for 5 years, with the latest figure at $2.8 million in Q1 2026.

• Quarterly Operating Leases fell 21.96% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 21.96% YoY) and the FY2025 annual result came in at $3.0 million, down 20.45% from the prior year.
• Operating Leases slipped to $2.8 million in Q1 2026 per EWTX's latest filing, from $3.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $4.8 million in Q1 2023 and troughed at $1.6 million in Q2 2022.
• A 5-year average of $3.5 million and a median of $3.6 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2024: Operating Leases soared 191.56% in 2023, then retreated 25.03% in 2024.
• Over 5 years, Operating Leases stood at $3.8 million in 2022, then advanced by 16.68% to $4.4 million in 2023, then decreased by 15.63% to $3.7 million in 2024, then declined by 20.45% to $3.0 million in 2025, then declined by 6.72% to $2.8 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $2.8 million, $3.0 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.